Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
Aug 25, 2026, 11:41Gregory Lip: Don’t Miss – €1,000 Mechanical Thrombectomy Grant
-
Aug 25, 2026, 11:35Applications Now Open for ASH26 Scientific Workshops
-
Aug 25, 2026, 11:34Louise St. Germain Bannon: ISTH is Looking for a Director of Strategic Partnerships and Business Development
-
Aug 25, 2026, 11:25Wolfgang Miesbach: Haemophilia and Ageing – A Joint ISTH/EAHAD Session at ISTH 2026
-
Aug 25, 2026, 11:18Caitlin Raymond: Your Blood Type Doesn’t Define Your Personality
-
Aug 25, 2026, 11:18N. Mariana S. Vasquez: USMLE Key Differences – Marfan Syndrome vs. Homocystinuria
-
Aug 25, 2026, 11:16Miguel Bronchud: Making Monoclonal Antibodies Safer in Pregnancy
-
Aug 25, 2026, 11:14Natalie Arnold: Germany Recognizes Low-Dose Colchicine in CVD Prevention
-
Aug 25, 2026, 11:08William Aird: Iron Deficiency vs. Inflammation – Look at the Minivans